The AMA testified before the U.S. Senate Special Committee on Aging this week, stating that the practice of direct-to-consumer (DTC) advertising of drugs remains controversial, but will most likely remain.
A 1999 study found that half of patients incorrectly believed drug ads are pre-approved by the Food and Drug Administration, and 43 percent incorrectly believed that only risk-free drugs are advertised.